Latest Oncology News

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Caroline Seymour

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Kristie L. Kahl

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

Chris Ryan

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

Kristi Rosa

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Ariana Pelosci

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Latest Oncology Videos

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast

Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer

Rechallenge Strategies, Practice Logistics, and Patient Communication Regarding ADCs in Breast Cancer

Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer

Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

Clinical Impact of Datopotamab Deruxtecan in First Line Triple Negative Breast Cancer

CNS Recurrence and the Expanding Role of ADCs in Breast Cancer

Outcomes With Blinatumomab in Younger Adults With BCR:ABL1–negative B-ALL

Emerging Strategies for ALK+ NSCLC

Endometrial Cancer: Interpreting dMMR and Post-Adjuvant Activity from LEAP-001

Assessing Relapse: Clinical, Biological, and Patient-Centered Considerations

All Oncology News

EGFR-Mutated NSCLC: Key Data Highlights from ESMO 2025

December 3rd 2025

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Riley Kandel

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

CMS Releases Final CY 2026 Hospital Outpatient Prospective Payment System (OPPS): Implications for Nuclear Medicine

December 3rd 2025

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

The Centers for Medicare and Medicaid released the final rule for the CY Hospital OPPS, which will take effect in 2026.

FDA Approves Pirtobrutinib for Relapsed or Refractory CLL/SLL

December 3rd 2025

Courtney Flaherty

The FDA has granted traditional approval to pirtobrutinib for covalent BTK inhibitor–exposed, relapsed/refractory CLL or SLL.

TARA-002 Intravesical Therapy Generates High CR Rate in BCG-Naive NMIBC With CIS

December 3rd 2025

Courtney Flaherty

Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.

Silevertinib Drives CNS Responses in First-Line NSCLC With Non-Classical EGFR Mutations

December 3rd 2025

Chris Ryan

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

Dr Brown Discusses Neuroendocrine Tumors

December 3rd 2025

Rebecca Brown, MD, PhD

Rebecca Brown, MD, PhD, discusses neuroendocrine tumors.

Dr Quiroga Shares Breast Cancer Insights

December 3rd 2025

Dionisia Quiroga, DO, PhD

Dionisia Quiroga, DO, PhD, discusses breast cancer insights.

Maintenance Fuzuloparib Displays PFS Benefit in Newly Diagnosed, Advanced Ovarian Cancer

December 3rd 2025

Kyle Doherty

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

Updated FIREFLY-1 Data Further Support Tovorafenib as a SOC in R/R Pediatric Low-Grade Glioma

December 3rd 2025

Kristi Rosa

Tovorafenib produced deep, durable responses in pLGG, with long treatment-free intervals and minimal tumor rebound after therapy.

Safety Considerations for BRAF Inhibition in CNS Malignancies

December 3rd 2025

Patrick Y. Wen, MD

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the safety profile and management of toxicities associated with BRAF inhibitors in central nervous system tumors.

Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025

December 3rd 2025

Ashling Wahner

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Detailing the Exploration of Plixorafenib in CNS Malignancies

December 3rd 2025

Patrick Y. Wen, MD

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

December 3rd 2025

Sarah Rutherford, MD

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

Lutetium Lu 177 Vipivotide Tetraxetan Shows Activity in Oligometastatic HSPC

December 2nd 2025

Kyle Doherty

Lutetium Lu 177 vipivotide tetraxetan was effective in patients with oligometastatic hormone-sensitive prostate cancer.

See All News